ClinicalTrials.gg
Not yet recruitingNCT07708285Updated Jul 16, 2026

Luvometinib in Combination With Serplulimab for NF2-Related Tumors

A Phase 1/2 interventional study of Luvometinib and Serplulimab in NF2-related Schwannomatosis, NF2 and Neurofibromatosis Type 2, sponsored by Beijing Tiantan Hospital. Not yet recruiting at 5 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by Beijing Tiantan Hospital · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is an investigator-initiated, exploratory, multicenter, open-label, single-arm clinical trial and a substudy of the Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2). The study aims to evaluate the safety, tolerability, and preliminary efficacy of luvometinib in combination with serplulimab in patients with NF2-related schwannomatosis (NF2-SWN) with progressive tumors.

Read the detailed description

NF2-related schwannomatosis (NF2-SWN) is a rare autosomal dominant disorder characterized by multiple central nervous system tumors, most commonly vestibular schwannomas and meningiomas. Although current treatments such as surgery and radiotherapy can provide disease control, they are not curative and are associated with cumulative neurological morbidity and potential risk of secondary malignancies. There remains a significant unmet need for effective systemic therapies.

This investigator-initiated study is conducted as a substudy within the Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2). The trial evaluates luvometinib in combination with serplulimab in patients with progressive NF2-SWN.

Luvometinib (FCN-159) is a selective MEK1/2 inhibitor with antitumor activity in NF1-associated tumors. Serplulimab (HLX10) is an anti-PD-1 monoclonal antibody approved for multiple solid tumors. Preclinical evidence suggests that MEK inhibition may enhance tumor immunogenicity and synergize with immune checkpoint blockade.

The study aims to assess the safety, tolerability, and preliminary efficacy of this combination in NF2-SWN.

02

Conditions studied

  • NF2-related Schwannomatosis
  • NF2
  • Neurofibromatosis Type 2
  • Vestibular Schwannoma
  • Meningioma
03

In context

Neurofibromatosis 2

47 studies on the registry are indexed under Neurofibromatosis 2; 10 are open to participants now.

This study's planned enrollment of 30 is above the median of 21 across 36 interventional studies indexed under Neurofibromatosis 2.

Browse Neurofibromatosis 2 studies →

Lead sponsor

Beijing Tiantan Hospital is the lead sponsor of 494 studies on the registry; 298 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must meet the diagnostic criteria for NF2-SWN.
  2. Presence of at least one measurable target tumor, either vestibular schwannoma or meningioma, with MRI-documented volumetric progression within the past 36 months or clinical symptom progression related to the target tumor.
  3. The target tumor is considered unsuitable for surgery because of high risk.
  4. Age >=18 years at the time of screening.
  5. >=70 or performance status 0 or 1.
  6. Adequate organ function based on laboratory tests obtained within 14 days before screening.
  7. Participant must be able to understand the study and voluntarily sign .

Exclusion criteria

Exclusion Criteria:

  1. Pregnant, planning to become pregnant, or currently breastfeeding.
  2. Participation in another interventional clinical trial within the past 4 weeks, or radiation therapy to target lesion(s) within the past 3 years.
  3. Severe adverse reactions or intolerable toxicity from prior or MEK inhibitors.
  4. Concomitant active , uncontrolled infections, or active diseases.
  5. Severe cardiac, hepatic, renal, gastrointestinal, or ophthalmic diseases.
  6. Any other factor that may compromise participant safety or study integrity.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Luvometinib + Serplulimab

    Subjects will receive luvometinib 8 mg by mouth once daily in combination with serplulimab 4.5 mg/kg intravenously every 3 weeks for up to 12 cycles (28 days per cycle).

    Drug: Luvometinib · Drug: Serplulimab

Interventions

  • Oral once daily per predetermined dosage per protocol.

    Also known as: FCN-159

  • Intravenous infusion per predetermined dosage per protocol.

    Also known as: HLX10

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) or Hearing Response Rate (HRR)

    Vestibular schwannoma: HRR is defined as WRS improvement exceeding the 95% critical difference from baseline; if baseline WRS is \<20%, HRR is defined as a PTA decrease of at least 10 dB. Meningioma: ORR is defined as at least a 20% reduction in target tumor volume from baseline.

    Time frame: 12 months

Secondary outcomes

  1. Incidence of Adverse Events

    Percentage of participants who experience at least one adverse event. Adverse events will be coded and graded according to NCI CTCAE v5.0.

    Time frame: From first dose through 30 days after last dose (up to 12 months)

  2. Maximum Severity Grade of Adverse Events

    Maximum NCI CTCAE v5.0 grade of adverse events experienced by each participant during the reporting period.

    Time frame: From first dose through 30 days after last dose (up to 12 months)

  3. Incidence of Serious Adverse Events

    Percentage of participants who experience at least one serious adverse event.

    Time frame: From first dose through 30 days after last dose (up to 12 months)

  4. Incidence of Dose Modifications

    Percentage of participants who require at least one dose modification due to an adverse event.

    Time frame: From first dose through 30 days after last dose (up to 12 months)

  5. Incidence of Treatment Interruptions

    Percentage of participants who require at least one treatment interruption due to an adverse event.

    Time frame: From first dose through 30 days after last dose.

  6. Incidence of Treatment Discontinuations

    Percentage of participants who discontinue study treatment due to an adverse event.

    Time frame: From first dose through 30 days after last dose.

07

Study locations

5 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2026; primary completion for Dec 2028, 29 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2026
First posted
Jul 16, 2026
StartEst.
Jul 31, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2029
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07708285
Responsible party
Sponsor
First posted
Jul 16, 2026
Start date
Jul 31, 2026 (estimated)
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Jul 16, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Luvometinib

Start the discussion